14 Biotech Stocks with High Potential

Page 8 of 13

6. Soleno Therapeutics, Inc. (NASDAQ:SLNO)

Analyst Upside: 102.67%

Number of Hedge Fund Holders: 52

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the best biotech stocks with high potential. In a report released on October 3, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Soleno Therapeutics, Inc. (NASDAQ:SLNO) and set a price target of $145.00.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) reported in its fiscal Q2 2025 results that it used $12.6 million of cash in its operating activities during the three months ended June 30, 2025. The company had $293.8 million of cash, cash equivalents, and marketable securities at quarter end

In addition, cash at the end of fiscal Q2 2025 excluded $230 million of gross proceeds that Soleno Therapeutics, Inc. (NASDAQ:SLNO) raised in July through an underwritten offering of common stock.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) also reported that product revenue, net, for the quarter reached $32.7 million.

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is a clinical-stage biopharmaceutical company that develops and commercializes novel therapeutics to treat rare diseases.

The company focuses on the treatment of neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet that treats Prader-Willi Syndrome (PWS).

Page 8 of 13